Biotech Startups

Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.

2 investors

Endodiag develops non-invasive diagnostic tests based on blood biomarkers to identify endometriosis in women, addressing a condition currently requiring surgical diagnosis. The company also creates solutions to map patient disease for personalized treatment and fertility management.

2 investors

Endogene is a biotech company focused on uterine biology, developing tools to improve the understanding, diagnosis, and treatment of uterine diseases.

2 investors

Enduro develops synthetic biology technology for large-scale fermentation processes, helping bioproduction companies maintain high cell productivity and strain stability during bio-based manufacturing. The company provides genetic tools and RNA sequencing services to prevent production decline in cultivated cells across diverse bioproducts.

2 investors

Company whose formation and launch the LifeSci team supported.

2 investors

Engender develops a patented laser-based technique for sorting male and female sperm cells to enable gender selection at the sperm stage, targeting the dairy industry to reduce unwanted male calves. Its precision breeding technology serves dairy farmers and animal genetics providers, helping improve animal welfare and farm economics.

2 investors

Ennov provides an AI-powered unified compliance software platform for life sciences companies, covering regulatory, quality, clinical, pharmacovigilance, and commercial processes across the product lifecycle. Its solutions manage content, data, and workflows for regulated industries and are used by over 650 life sciences companies worldwide.

2 investors

Enoda develops synthetic cytokine receptors, called MIMICs, that link therapeutic "Signal 3" cytokine functions to controllable inputs to engineer cell therapies without systemic toxicity. It offers a platform and discovery screens to optimize CAR T cells, regulatory T cells, macrophages, and stem cells for autologous, allogenic, and in vivo cell therapy partners.

2 investors

ENPICOM provides a software platform for biologics discovery that orchestrates analysis workflows, handles immune-repertoire and antibody sequence analysis, and integrates assay and sequencing data for drug development scientists and teams. The platform processes billions of sequences and delivers results directly to scientists without requiring dedicated bioinformatics support.

2 investors

En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications. It aims to expand the accessible RNA design space and manufacturing capacity for RNA-based drugs.

2 investors

Enrich Biosystems develops TROVO, a fluidics-free benchtop instrument that compartmentalizes standard culture plates into thousands of hydrogel microwells for high-throughput functional screening, imaging, and live recovery of cells. It serves cell therapy and life sciences researchers working on applications such as CAR-T cell selection, cell line development, and single-cell omics enrichment.

2 investors

Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD). The drug candidate, acquired from EA Pharma, is designed as an oral alternative to biologic therapies and as an anchor for oral combination therapy, and is currently in Phase 1 clinical development.

2 investors

Entelexo develops engineered exosome therapeutics for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company uses a proprietary platform to design exosomes that communicate with multiple diseased cell types simultaneously, replacing traditional single-target treatments.

2 investors

Envirotainer provides temperature-controlled solutions for the pharmaceutical supply chain, serving healthcare providers and pharmaceutical distributors. The company offers tailored solutions across different stages of the pharmaceutical lifecycle.

2 investors

Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care. The device aims to enable rapid therapy adjustment for patients and reduce healthcare costs by bringing laboratory testing capabilities to clinical settings.

2 investors

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.

2 investors

EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.

2 investors

EPICS is a biotech company developing plant biology and protein engineering technology to produce agricultural inputs such as crop protection products and biostimulants. It applies plant molecular farming and epigenetics research to create scalable expression systems for high-value protein production in agriculture.

2 investors

Epidarex is a venture capital firm that invests equity in early-stage life science and health technology companies, particularly university spin-outs and startups in under-ventured research hubs across the UK and US. The firm leverages its network of scientists, industry executives, and regulatory experts to support portfolio companies in translating research into commercial healthcare businesses.

2 investors

Epigene Labs develops AI-powered tools for analyzing genomic data and precision oncology research, serving biopharmaceutical companies and cancer researchers. The company builds software platforms and conducts translational research to support the development of personalized cancer therapies.

2 investors

Epigenica is a life sciences company working in multi-omics, biomarker discovery, and diagnostics. It develops advanced technologies for the life science and healthcare sectors.

2 investors

A company bringing together expertise in genetics, pathology, medicine, and bioinformatics to develop data science and AI solutions in the healthcare field.

2 investors

Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.

2 investors

Epion Therapeutics develops a minimally-invasive cross-linking treatment system called EpiSmart for keratoconus, a corneal disease, designed to preserve vision without disrupting the corneal epithelium. The company aims to bring early intervention treatment to patients globally.

2 investors